Cancer Research

The oncology sector is shifting its primary focus from simply managing terminal disease to achieving functional cures that allow patients to live long, healthy lives. This transition marks a departure from the historical reliance on broad-spectrum treatments that often came with debilitating side

The approval of Guardant360 CDx as a companion diagnostic for AstraZeneca’s camizestrant marks the first time a liquid biopsy has been authorized for continuous monitoring of cancer evolution. This regulatory milestone fundamentally alters the management of advanced breast cancer by allowing

While immunotherapy was previously confined to treating advanced stages of the disease, new evidence shows its efficacy in earlier, resectable settings. Gastric cancer has long remained a formidable opponent within the global oncology landscape, currently ranking as the fifth most common cancer

The inherent inefficiencies of the autologous model are tied to a one-batch-per-patient approach that restricts throughput and maintains high market prices for oncology treatments. While Chimeric Antigen Receptor (CAR) T-cell therapies have redefined oncology by providing life-saving results for

In the United States, 300,000 new cases of breast cancer are diagnosed annually, many of which will eventually progress to a more resistant metastatic state. For patients facing these advanced stages, the traditional arsenal of chemotherapy and hormonal blockers often loses its efficacy over time,

The synthesis of combination therapies and early detection creates a feedback loop that amplifies the effectiveness of modern cancer treatment protocols. This paradigm shift means oncologists no longer view cancer as a static entity confined to a single organ like the lung or breast. Instead, they